新銳醫藥:2023年報
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Innovative drugs continue to warm up! Joint policies in many places catalyze the strengthening of the pharmaceutical sector in Hong Kong stocks
Recently, support policies for the innovative pharmaceutical industry have been issued in many places, bringing a new market catalyst to the currently relatively deserted pharmaceutical stocks. The Hong Kong stock pharmaceutical sector is also active today.
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
Xinrui Pharmaceuticals (06108) announced annual results. The net loss attributable to shareholders was about HK$22.2 million, a year-on-year narrowing of about 71.5%
According to the Zhitong Finance App, Xinrui Pharmaceutical (06108) announced results for the year ended December 31, 2023, with revenue of about HK$50.2 million, a year-on-year decrease of 44.1%; net loss attributable to the company's owners was about HK$22.2 million, a year-on-year decrease of about 71.5%; and a loss of 1.33 HK cents per share. The decline in revenue was mainly due to the further strengthening of the hierarchical classification management policies for the adoption of antimicrobials in many regions of mainland China, and the adverse effects continued. As a result, demand for the Group's main product, second-generation cephalosporin products (1.0g), declined this year.
NEW RAY MEDIC: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Hong Kong pharmaceutical stocks bucked the trend, and Pharmacovigilance led their sector. Is the “Biosafety Act” or a biological variable?
① Why is the market paying attention to the Biosafety Act? ② How has Yao Ming Kangde performed recently?
New Ray Medicine International Forecasts Decline in 2023 Loss
New Ray Medicine International Holding (HKG:6108) expects a net loss of up to HK$30 million for the year 2023, down from HK$77.9 million in 2022, a March 15 filing on the Hong Kong bourse by the pharm
Xinrui Pharmaceuticals (06108.HK) expects a sharp reduction in annual losses
Gelonghui, March 15, 丨 Xinrui Pharmaceuticals (06108.HK) announced that the company expects to record a net loss of no more than HK$30.0 million for the year ended 31 December 2023, while in the previous year, the Group recorded a net loss of approximately HK$77.9 million. The sharp reduction in expected losses for fiscal year 2023 is mainly due to (i) no recording of equity settlement expenses on a share-based basis. The relevant expenses for FY2022 were approximately HK$10.4 million, as confirmed by the Group granting share options to directors and employees in FY2022, and the Group did not record any in FY2023
NEW RAY MEDIC: INSIDE INFORMATION - SUBSTANTIAL REDUCTION IN LOSS
Yao Ming Kangde was removed from BIO membership! Where will the domestic innovative drug sector go?
The path to the rise of innovative drugs doesn't seem easy!
Not only is Daimo bullish, but Xiaoma has taken steps to increase its holdings of the drug Ming Kangde. Major international banks are turning one after another, and the Hong Kong stock pharmaceutical industry is welcoming a “crouching and leap”?
① Hong Kong stocks of Innovative Pharmaceuticals soared at the end of yesterday. Collumbotai Biotech B rose 14.9%; Rongchang Biotech rose 14.8%; Connoya B rose 12.8%; ② Although “Yao Mao” Pharmaceutical Kangde Hong Kong shares closed down 1.16%, the decline narrowed sharply at the end of the session, and J.P. Morgan increased its holdings by 1.654 million shares, or HK$77.68 million.
Xinrui Pharmaceuticals (06108.HK) will hold a board meeting on March 25 to approve the annual results
Gelonghui, March 13, 丨 Xinrui Pharmaceutical (06108.HK) issued an announcement. The board of directors will meet on March 25, 2024 to consider and approve the Group's annual results and publication for the year ended December 31, 2023, and to consider whether to pay a final dividend (if any).
NEW RAY MEDIC: DATE OF BOARD MEETING
Express News | China Artificial Intelligence Industry Development Alliance plans to initiate the establishment of a “Biomedical Industry Working Group”
What is the biggest highlight of medicine this year? The new version of the basic drug catalogue expands traditional Chinese medicine and pediatric medicine and is expected to usher in benefits|Traditional Chinese Medicine 2024 outlook
Finance Association, Feb. 29 (Reporter Zhang Liangde) “The biggest highlight of the pharmaceutical industry this year is the expansion of the new version of the basic drug catalogue.
Hong Kong Stock Concept Tracking | Pharmaceutical companies' pricing is being loosened? The innovative drug sector is expected to usher in a beta market (with concept stocks)
On February 5, the National Health Insurance Administration issued a letter to relevant industry associations seeking comments on the “Notice on Establishing a Initial Price Formation Mechanism for Newly Launched Chemicals to Encourage High-Quality Innovation (Draft for Comments)”.
Heavy policy! “One province connected to the Internet, nationwide access” innovative drug market entry welcomed benefits
On the eve of the Lunar New Year, the pharmaceutical industry once again ushered in a major favorable policy.
CICC: The pharmaceutical sector has entered the value investment range. It is recommended to focus on overseas exports and opportunities to increase the localization rate
CICC released a research report saying that after more than 2 years of systematic adjustments, the pharmaceutical sector has entered the value investment range.
No Data